Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19
Authors:
- 10 March 2021
- journal article
- review article
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 8 (1) , 43-54
Abstract
The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19. Lay Summary The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.Keywords
This publication has 65 references indexed in Scilit:
- Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative MedicineInternational Journal of Molecular Sciences, 2017
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathologySeminars in Immunopathology, 2017
- Is Stem Cell a Curer or an Obstruction?Molecular and Cellular Biomedical Sciences, 2017
- Current Trends in Regenerative Medicine: From Cell to Cell-Free TherapyBioNanoScience, 2016
- Mesenchymal Stem Cells Manage Endogenous Tissue RegenerationThe Indonesian Biomedical Journal, 2016
- Body Management: Mesenchymal Stem Cells Control the Internal RegeneratorStem Cells Translational Medicine, 2015
- Secretion of immunoregulatory cytokines by mesenchymal stem cellsWorld Journal of Stem Cells, 2014
- Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL-37Stem Cells, 2010
- The Molecular Biology of Coronaviruses2006
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004